Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target
- PMID: 33338512
- DOI: 10.1016/j.jhep.2020.11.052
Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target
Erratum in
-
Corrigendum to: 'Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target' [J Hepatol 2021 (74) 1155-1166].J Hepatol. 2022 May;76(5):1242-1243. doi: 10.1016/j.jhep.2022.01.019. Epub 2022 Feb 24. J Hepatol. 2022. PMID: 35221117 No abstract available.
Abstract
Background & aims: Telomerase activation is the earliest event in hepatocellular carcinoma (HCC) development. Thus, we aimed to elucidate the role of telomere length maintenance during liver carcinogenesis.
Methods: Telomere length was measured in the tumor and non-tumor liver tissues of 1,502 patients (978 with HCC) and integrated with TERT alterations and expression, as well as clinical and molecular (analyzed by genome, exome, targeted and/or RNA-sequencing) features of HCC. The preclinical efficacy of anti-TERT antisense oligonucleotides (ASO) was assessed in vitro in 26 cell lines and in vivo in a xenograft mouse model.
Results: Aging, liver fibrosis, male sex and excessive alcohol consumption were independent determinants of liver telomere attrition. HCC that developed in livers with long telomeres frequently had wild-type TERT with progenitor features and BAP1 mutations. In contrast, HCC that developed on livers with short telomeres were enriched in the non-proliferative HCC class and frequently had somatic TERT promoter mutations. In HCCs, telomere length is stabilized in a narrow biological range around 5.7 kb, similar to non-tumor livers, by various mechanisms that activate TERT expression. Long telomeres are characteristic of very aggressive HCCs, associated with the G3 transcriptomic subclass, TP53 alterations and poor prognosis. In HCC cell lines, TERT silencing with ASO was efficient in highly proliferative and poorly differentiated cells. Treatment for 3 to 16 weeks induced cell proliferation arrest in 12 cell lines through telomere shortening, DNA damage and activation of apoptosis. The therapeutic effect was also obtained in a xenograft mouse model.
Conclusions: Telomere maintenance in HCC carcinogenesis is diverse, and is associated with tumor progression and aggressiveness. The efficacy of anti-TERT ASO treatment in cell lines revealed the oncogenic addiction to TERT in HCC, providing a preclinical rationale for anti-TERT ASO treatment in HCC clinical trials.
Lay summary: Telomeres are repeated DNA sequences that protect chromosomes and naturally shorten in most adult cells because of the inactivation of the TERT gene, coding for the telomerase enzyme. Here we show that telomere attrition in the liver, modulated by aging, sex, fibrosis and alcohol, associates with specific clinical and molecular features of hepatocellular carcinoma, the most frequent primary liver cancer. We also show that liver cancer is dependent on TERT reactivation and telomere maintenance, which could be targeted through a novel therapeutic approach called antisense oligonucleotides.
Keywords: Antisense oligonucleotides; Cancer; Chronic liver disease; Fibrosis; Liver; TERT; Telomeres; Treatment.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest Youngsoo Kim and A. Robert MacLeod are part of Ionis Pharmaceuticals, Carlsbad, CA, USA. Please refer to the accompanying ICMJE disclosure forms for further details.
Similar articles
-
The role of telomeres and telomerase in cirrhosis and liver cancer.Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):544-558. doi: 10.1038/s41575-019-0165-3. Epub 2019 Jun 28. Nat Rev Gastroenterol Hepatol. 2019. PMID: 31253940 Review.
-
Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing "stemness"-related markers.J Hepatol. 2013 Oct;59(4):746-52. doi: 10.1016/j.jhep.2013.05.011. Epub 2013 May 14. J Hepatol. 2013. PMID: 23685049
-
Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis.Cancer Genet Cytogenet. 1997 Jan;93(1):56-62. doi: 10.1016/s0165-4608(96)00329-9. Cancer Genet Cytogenet. 1997. PMID: 9062581
-
Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma.PLoS One. 2017 Aug 16;12(8):e0183287. doi: 10.1371/journal.pone.0183287. eCollection 2017. PLoS One. 2017. PMID: 28813500 Free PMC article.
-
Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data.Expert Opin Ther Targets. 2022 Sep;26(9):767-780. doi: 10.1080/14728222.2022.2147062. Epub 2022 Nov 18. Expert Opin Ther Targets. 2022. PMID: 36369706 Review.
Cited by
-
Evolving therapeutic landscape of advanced hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):203-222. doi: 10.1038/s41575-022-00704-9. Epub 2022 Nov 11. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36369487 Review.
-
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0. BMC Cancer. 2023. PMID: 37516867 Free PMC article. Clinical Trial.
-
Aberrant TERT expression: linking chronic inflammation to hepatocellular carcinoma†.J Pathol. 2025 Jun;266(2):130-133. doi: 10.1002/path.6421. Epub 2025 Apr 11. J Pathol. 2025. PMID: 40213897 Free PMC article. Review.
-
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.Nat Cancer. 2022 Apr;3(4):386-401. doi: 10.1038/s43018-022-00357-2. Epub 2022 Apr 28. Nat Cancer. 2022. PMID: 35484418 Free PMC article. Review.
-
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside.Exp Hematol Oncol. 2024 Aug 1;13(1):72. doi: 10.1186/s40164-024-00539-x. Exp Hematol Oncol. 2024. PMID: 39085965 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous